New radiation approach aims to control thymic cancer spread with fewer side effects
NCT ID NCT05354570
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a precise type of radiation called IMPRINT for people whose thymic cancer has spread to the lining of the lung (pleura). The main goal is to see if this treatment is safe and causes only mild side effects, especially lung inflammation. About 36 participants will receive radiation to the affected side of the chest, and researchers will track how well it controls the cancer over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 36 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2022
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 79 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provide written informed consent to participate on the study * Patients must have a pathologically confirmed diagnosis of thymic malignancy. Thymic carcinoma is allowed. * Patients must have radiologic or pathologic evidence of pleural metastases. Patients may have de novo stage IVA or recurrent disease in the pleura. Gross disease in the fissure is allowed if resected. * No evidence of extrathoracic metastatic disease or contralateral pleural/pericardial disease. * Patient age ≥ 18 years but ≤ 80 years at the time of consent * Karnofsky performance status ≥ 80% * Preoperative or Postoperative Pulmonary Function Tests: DLCO \> 40% predicted (corrected for Hgb) and FEV1 ≥ 35% (corrected for Hgb) * Glomerular filtration rate (GFR): ≥50 mL/min/1.73 m2 (must be calculated using estimated creatinine clearance (CrCl) by the Cockcroft-Gault (C-G) equation (Nephron 1976;16:31-41): CrCl (mL/min) = \[140 - age (years)\] x weight (kg) \[x 0.85 for female patients\] 72 x serum creatinine (mg / dL) ° In cases of concern about decreased renal function and potential high radiation dose to the kidneys, an optional nuclear medicine kidney function scan may be performed prior to radiation therapy to determine the functional contribution of each kidney. Exclusion Criteria: * Continuous oxygen use * Patients with an acute flare of myasthenia gravis requiring addition of new medication in the past 6 months * Prior nephrectomy on the contralateral side of the pleural metastases * Prior thoracic radiation therapy preventing hemithoracic pleural IMRT. Prior thymic bed radiation is allowed. Prior pleural SBRT is allowed. * Patients undergoing extrapleural pneumonectomy. Other surgical resection approaches of the pleural nodules (ex: P/D, debulking/metastasectomy) are allowed. Surgical resection of the primary thymic tumor is allowed. * Acute congestive heart failure requiring hospitalization within the past 30 days. * COPD requiring chronic oral steroid therapy of \> 10 mg prednisone daily or equivalent at the time of registration. Inhaled corticosteroids are allowed * Unstable angina requiring hospitalization and/or transmural myocardial infarction within the last 3 months * History of interstitial lung disease * Pregnant or lactating women * Men or women not using effective contraception
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pleural metastases are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (Limited protocol activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (Limited protocol activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (Limited protocol activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (Limited protocol activities)
RECRUITINGRockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (Limited protocol activities)
RECRUITINGHarrison, New York, 10604, United States